Gut Microbes Hold the Key to Unlocking Soy’s Health Benefits, Review Finds

A sweeping systematic review of randomized clinical trials has delivered a sobering verdict: decades of attempts to convert people who cannot produce equol—a highly bioactive metabolite of soy isoflavones—into producers have largely failed. The review, published in Food Science & Nutrition, analyzed twelve randomized controlled trials encompassing 730 participants at baseline, and found that none of the interventions tested achieved statistically significant conversion of equol nonproducers into producers. The findings carry weighty implications for the design of soy-based nutritional interventions, particularly in Western populations where the potential benefits of equol remain largely untapped.

Equol is produced exclusively by gut bacteria from daidzein, one of the principal isoflavones in soy. Unlike its precursor, equol is a selective estrogen receptor-beta agonist with greater antioxidant activity and bioavailability, and it can cross the blood–brain barrier, where laboratory studies suggest it exerts neuroprotective effects against toxin-induced cytotoxicity. The capacity to produce equol, however, is strikingly uneven across the globe: up to 70 percent of East Asians, whose habitual diets are rich in soy, are producers, compared with only 20 to 30 percent of Western populations. This disparity may help explain why randomized trials of soy isoflavones in Europe and the United States have yielded inconsistent results while observational studies in East Asia keep linking equol—not soy isoflavones themselves—to favorable outcomes.

The observational evidence is compelling. Equol producers in East Asian cohorts show lower aortic calcification, reduced risk of coronary heart disease and stroke, lower serum triglycerides, improved endothelial function, and reduced carotid intima-media thickness. Cross-sectional studies have also associated equol production with fewer postmenopausal symptoms and lower risk of mild cognitive impairment. A prospective cohort study in Chinese adults found that producers harbor richer gut microbiota, with enrichment of short-chain fatty acid–producing genera and depletion of inflammation-associated taxa. Taken together, these findings suggest that equol production may be a marker of a broader, functionally favorable gut ecosystem rather than a simple pharmacological trait.

To assess whether that trait can be instilled, the researchers followed PRISMA guidelines and registered their protocol with PROSPERO, searching PubMed, Embase, and Web of Science from the mid-1990s through January 2026. From 503 initial records, screening and full-text review winnowed the field to twelve eligible randomized trials. Eight studies enrolled only women, and six focused exclusively on postmenopausal women. Interventions fell into three broad categories: soy isoflavones alone, soy combined with probiotics or prebiotics, and fermented soy products or other dietary additions such as wheat bran and seaweed. Durations ranged from a single dose over 48 hours to 2.5 years, and eight trials used crossover designs.

The results were uniformly null with respect to conversion. In the isoflavone-only trials, neither ten weeks of high-dose soy nor six months to 2.5 years of supplementation changed producer status. The probiotic and prebiotic trials—most using Lactobacillus acidophilus and Bifidobacterium longum strains, sometimes with fructo-oligosaccharides—likewise failed to convert nonproducers, though two studies hinted that probiotics might enhance equol excretion among women who were already producers. Fermented soymilk converted two of eight participants in one small trial, a trend that did not reach significance, while seaweed combined with isoflavones increased equol secretion in existing producers without changing anyone’s status. Quality assessment using the National Heart, Lung, and Blood Institute tool rated seven trials as fair and five as poor; not one met the criteria for good quality, largely due to missing power calculations and dropout rates exceeding 20 percent in five studies.

The review’s authors argue that these failures reflect the ecological complexity of the gut microbiome rather than biological impossibility. Equol conversion depends on a limited consortium of anaerobic bacteria, notably Slackia isoflavoniconvertens and Adlercreutzia equolifaciens. Crucially, the probiotic strains deployed in the reviewed trials are not equol converters themselves; their beta-glucosidase activity can hydrolyze isoflavone glucosides into aglycones, but they cannot perform the subsequent reductive steps from daidzein to equol. Increasing substrate availability, in other words, accomplishes little when the specialized microbial machinery is absent. Japanese population studies have detected equol-converting bacteria in both producers and nonproducers at comparable levels, indicating that the broader community context—abundance, metabolic activity, and the surrounding microbial network—determines whether conversion actually occurs.

Adding a further complication, equol-producing status may not be a fixed trait. In the Women’s Isoflavone Soy Health trial, 14 percent of postmenopausal and 11 percent of premenopausal participants changed producer status at some point during follow-up, and status crossover occurred even among placebo recipients. A four-year prospective cohort of 498 Japanese adults reported that 26.1 percent of participants had unstable producer status across annual assessments despite comparable daidzein intake. Notably, stable producers exhibited significantly higher gut microbiota diversity and distinct microbial composition compared with both unstable producers and nonproducers, suggesting that only sustained equol production supported by a favorable ecosystem confers the full health benefits. Unstable producers, whose intermediate microbial profiles suggest they may be more amenable to intervention, could represent a key target population for future trials.

Methodological weaknesses compound the problem. Only four of the twelve trials used the standardized three-day soy challenge to establish baseline producer status, and just one applied the reference-standard cutoff of a log-transformed urinary equol/daidzein ratio greater than −1.75. Measurement approaches varied widely, from 24-hour urine collections to overnight urine or serum samples. Ten of the twelve trials were conducted in Western countries, and none included sufficient pre- and post-treatment fecal microbiome analyses—a critical gap that leaves open the question of whether interventions altered microbial community structure even when they failed to induce equol production. The heterogeneity of isoflavone formulations, doses, and delivery routes further obscures whether null results reflect true biological inertness, insufficient bioavailability, or simply inadequate duration.

There are glimmers of promise outside the randomized evidence. Nonrandomized studies suggest that longer-term, higher-dose soy exposure can convert nonproducers: one trial providing one liter of soymilk daily for 16 weeks converted 8 of 20 nonproducers, and vegetarian populations in Western countries produce equol at roughly four times the rate of nonvegetarians, approaching Asian levels—likely because fiber-rich plant-based diets cultivate the fermentative microbial environment the daidzein-to-equol pathway requires. Preclinical work has shown that Slackia isoflavoniconvertens can stably colonize the intestine and convert daidzein to equol in gnotobiotic rat models, providing direct support for prioritizing true equol-converting organisms, potentially paired with prebiotic substrates that selectively sustain them, in future human trials.

The review concludes with a roadmap for the field. Future randomized trials should enroll both sexes across a wide age range, extend intervention durations, employ shotgun metagenomics and targeted quantitative PCR to track equol-converting bacteria, and adopt the standardized urinary equol/daidzein ratio with repeated measurements to avoid misclassification. Trials should also distinguish explicitly among three outcomes—de novo conversion, enhancement of production in existing producers, and stabilization of status in unstable producers. With an ongoing US clinical trial currently testing equol supplementation for cardiovascular and brain health in aging populations, the stakes of getting this right are rising. The authors caution that the negative findings should not be read as proof that conversion is impossible; rather, they reflect the limits of short-term, one-size-fits-all interventions applied to a complex microbial ecosystem. Unlocking equol’s benefits for the majority of Western adults who lack it may require reshaping the gut community itself—a far more ambitious project than simply adding soy to the menu.

Subject of Research: Randomized clinical trials of dietary interventions aimed at converting equol nonproducers to producers through gut microbiome modulation

Article Title: Converting Equol Nonproducers to Producers: A Systematic Review of Randomized Clinical Trials

Article References: Li, J., Li, M., Aboushanab, S., Ebeid, M., Hatanaka, R., Iida, M., Takase, M., Jacobs, I., Gusmanov, A., Hirata, A., Miyagawa, N., Nakaya, N., Sugiyama, D., Tilves, C., Hozawa, A., Li, X., Mueller, N. T., Benos, P. V., & Sekikawa, A. (2026). Converting Equol Nonproducers to Producers: A Systematic Review of Randomized Clinical Trials. Food Science & Nutrition, 14(10), Article e72394. https://doi.org/10.1002/fsn3.72394

Image Credits: AI Generated

DOI: 10.1002/fsn3.72394

Keywords: equol, soy isoflavones, daidzein, gut microbiome, systematic review, randomized clinical trials, probiotics, prebiotics, menopause, cardiovascular health, phytoestrogens, nutrition